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Cancer registries provide data on the occurrence of cancer in
the population, and are a considerable resource for clinical
and epidemiological research. Early cancer registries had
their origin in the realisation by far-sighted physicians that
improvements in the diagnosis and treatment of cancer
would come to depend on the availability of complete and
reliable data which only population-based cancer registries
could provide. Thus the Connecticut Tumor Registry and the
Danish Cancer Registry began operation in 1935 and 1942,
respectively, with the voluntary notification of cancer patients
from hospitals and their attending physicians. Such
notifications were deemed to be an extension of patient care,
and the data were ipso facto considered to be confidential,
and thus subject to local ethical practice. This concept has
stood the test of time. No cancer registry has breached the
confidentiality of the information entrusted to it.
Cancer registration has expanded considerably: there are
now more than 250 population-based cancer registries in
operation in over 60 countries. As these registries mature,
they are increasingly being used for a wide variety of clinical
and epidemiological research (Jensen & Storm, 1991; Cole-
man et al., 1992).
Today, however, confidentiality is an issue of increasing
concern to many cancer registries, both new and established.
Among the general public, there is increasing concern about
the existence of large electronic databases which contain data
about named or otherwise identifiable individuals and which
can be linked with other such databases. Both the Council of
Europe (COE, 1981) and the EEC (CEC, 1984) have issued
recommendations relating to the confidentiality of individual
data in automated databases. A number of governments have
passed laws on data protection, designed primarily to protect
their citizens from possible abuse of individual data about
them which is held on such databases. The objectives behind
such guidelines and legislation are above criticism, but there
have sometimes been unfortunate side-effects: in some count-
ries, such laws also impede the work of cancer registration,
and research based on cancer registry records may become
either difficult or impossible (Heasman, 1982; Meisner et al.,
1990; Muir & Demaret, 1982; 1991; Thiele, 1990; Sietmann,
1991).
In this article the issue ofconfidentiality in cancer registries
is discussed, both as a contribution to the public debate and
to assist cancer registries in drafting or revising their own
rules and regulations.
The International Association of Cancer Registries
(IACR), formed in 1966, is a professional society whose
members are interested in the development of cancer registra-
tion as a tool for cancer control (Parkin et al., 1985) and in
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the application of cancer registries to cancer research. At its
annual scientific meeting in Hamburg, FRG, in August 1990,
the IACR adopted a policy statement on the provision of a
legal basis for population-based cancer registries. The IACR
statement included support for the principle that data concern-
ing individuals with cancer should be strictly confidential, but
noted that full respect for the confidentiality of such data
need not prevent the safe, efficient and useful operation of
cancer registries, as shown by worldwide experience over
many years.
Need for individual data
It is important to stress both the value of population-based
health research for the control and prevention of cancer
(Parkin et al., 1985) and the essential nature of access to
medical records with individually identifiable information in
the conduct of such research. In testimony before a US
congressional committee on government information and in-
dividual rights in 1979, for example, Gordis and Gold (1980)
identified a number of major contributions to the understan-
ding of disease, all derived from epidemiological studies in
which individual medical records were used, either directly,
or to identify subjects suitable for further study: some of the
major advances involving cancer are listed in Table I. In
assessing the challenge posed by current public health prob-
lems, especially cancer, they pointed out that 'the effects on
human health of new drugs and other chemicals in the
environment can only be identified through epidemiologic
and other investigations, most of which depend on the
availability of medical records'.
The US National Research Council recently set up a Panel
on Confidentiality and Data Access to consider this issue. In
inviting comments, the Panel emphasised 'the balance that
must be struck between protecting the confidentiality of in-
Table I Someadvances in understanding ofcancermade from studies
requiring the use ofindividual medical recordsa
Cigarette smoking is associated with cancers ofbladder, lungand other
organs, as well as with coronary heart disease and other conditions.
Cancer risk increase is associated with occupational exposure to
asbestos, vinyl chloride, and other chemicals.
Radiation exposure is associated with an increase in risk ofleukaemia
and cancer.
Vaginal adenocarcinoma risk is increased in the daughters of women
who received diethylstilboestrol during the pregnancy.
Endometrial cancer risk is increased in women taking oestrogens for
postmenopausal symptoms.
Understanding ofpopulation trends in cancer survival.
aAdapted from Gordis and Gold (1980).
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formation provided by persons or businesses for statistical
purposes and the need to make publicly-collected data widely
available for legitimate research and statistical uses.'
The UK Medical Research Council (MRC) recently
revised its 1972 statement on the principles and standards of
practice expected of researchers who use personal medical
data (MRC, 1985). The MRC statement points out that
doctors have a duty to build on the knowledge gained from
treating patients; that medical advance often depends on
pooling the experience of many doctors; and that 'advances
made in this way are so important that the council believes
that, provided every practical step has been taken to
safeguard confidentiality and to ensure that no disadvantage,
harm, distress or embarrassment is suffered by any individual
as a consequence, there should be no impediment to the use
of medical information in research'.
Effective cancer registration requires the collection and
linkage of data about individuals with cancer, often from
several different sources, over a number of years, from the
diagnosis of the cancer until the death of the individual
(Jensen et al., 1991). It is essential that personal identifiers,
including the individual's name and birthdate, be used in
collecting these data, for the following reasons:
(a) to eliminate multiple counting of a single tumour
(which would otherwise seriously inflate estimates of cancer
occurrence in the population) by combining data about one
individual from various sources at the time of initial cancer
registration;
(b) to enable a tumour record to be completed with data
obtained subsequently about recurrence, metastasis, new
primary cancers, and death;
(c) to ensure that data about individuals in the registry
are accurate, and can be readily corrected or updated;
(d) to enable production of cancer survival statistics. By
following up patients registered with cancer, or by matching
cancer registrations with death certificates, it is possible to
assess the survival of all persons with cancer in a defined
population. Survival from cancer in the population as a
whole is frequently different from survival in selected series
of patients, such as those recruited to clinical trials. Cancer
survival can also be assessed by clinical stage or extent of
spread at diagnosis, by type of treatment or by other
variables recorded at cancer registration, such as
socioeconomic category (Karjalainen & Pukkala, 1990). This
in turn enables definition of prognostic variables and the
design of early detection and treatment campaigns;
(e) to enable epidemiological studies of cancer to be car-
ried out. The argument here closely parallels that underlying
the notification of infectious diseases: it may only be possible
to investigate infectious disease outbreaks effectively if
identifiable individual case reports of the disease are
available. To investigate possible causes of cancer, for exam-
ple in case control studies, it is often necessary to contact
patients to obtain information on past exposure to chemicals
or other agents which may have caused their cancer.
The IACR statement notes that adequate safeguards for
the individual's right to privacy can be obtained by
adherence to an appropriate code ofconduct in the operation
of the cancer registry, just as in the operation of surveillance
systems for notifiable sexually transmitted diseases and other
infectious diseases, or in the operation of hospital records
systems. Administrative restrictions on cancer notification -
such as the requirement that patients give written or verbal
consent for data about their cancer to be entered into a
registry - produce uncontrollable selection bias and distor-
tion of incidence data which seriously detract from the
usefulness of the data collected. The position of the MRC is
similar: 'consideration has been given to the question of
whether [transfer of information from medical records for the
purpose of research] requires the explicit consent of the
patient. [ . . ] The Council considers that, subject to
scrupulous safeguards about confidentiality, information
about patients can properly be available for medical research
without their explicit consent, as it has been in the past'
(MRC, 1985).
Legal basis of cancer registration
The legal basis for cancer reporting during the period
1983-1987 is known for some 150 population-based cancer
registries, in 50 countries, which have been invited to con-
tribute to the next volume of Cancer Incidence in Five
Continents, the international compendium of cancer inci-
dence data (Parkin et al., in preparation). The pattern is
similar in all regions of the world (Table II). Just over half
(55%) of the registries obtain reports on a purely voluntary
basis from physicians, hospitals and other institutions
treating cancer patients. For some 38% of registries, report-
ing is required either by laws of the state or by local admini-
strative regulations, while for the remaining seven per cent of
registries, the legal basis of reporting is mixed, some sources
being required to report all diagnosed cancers, while others
cooperate on a voluntary basis. Of the 105 registries included
in volume V of Cancer Incidence in Five Continents, cover-
ing the period 1978-1982, 62 (59%) relied on voluntary
reporting. Among registries which had begun operation since
1970, the proportion was slightly higher (64%) (Muir et al.,
1987). There is thus no evidence of any major recent shift
toward mandatory reporting of cancer. In the EEC, 85% of
registries still received cancer notifications on a voluntary
basis in 1987 (Coleman & Demaret, 1988).
Where cancer is a disease that must be notified by law, the
doctor or institution reporting the cancer to the registry will
expect indemnity from legal action for breach of medical
confidentiality; this may make it easier to encourage coopera-
tion with cancer registration activities. Even where there is a
legal requirement to report cancer, however, it is not easily
enforceable, and there is little evidence that the mere
existence of such a requirement can ensure completeness of
registration, unless the necessary infrastructure for cancer
registration is already in place. In the cancer registry of
Finland, for example, reporting was voluntary until 1960,
when it became compulsory: no difference was observed in
the level of registration (Muir & Demaret, 1982). By con-
trast, the legal requirement to report cancers to the Turkish
Ministry of Health since 1983 has resulted in less than a
quarter of the expected number of cancer registrations,
whereas in Denmark, cancer registration was voluntary from
1943 onwards, and had been largely complete for many years
before notification of cancer became obligatory in 1987.
Laws designed to protect individual privacy may have the
additional but unintended effect of making effective cancer
registration impossible: for example, the number of cancers
reported to the cancer registry in Hamburg, FRG, fell from
10,000 a year to just two cases in 1980-1981, owing to
apprehension among physicians about possible legal conse-
quences of reporting cancers in their patients to the registry,
following a change in the rules governing transfer of such
information between the registry and the Ministry of Health
(Muir & Demaret, 1991). Since 1985, a special law has
allowed physicians to report cases of cancer to the registry,
but subject to the patient's consent (Thiele, 1990): it will be
some time before the effects of this legislation can be
evaluated.
If legislation is required, it should enable efficient and
confidential reporting of cancer. Such a law should explicitly
state that a cancer patient either should be (mandatory) or
may legally be (voluntary) reported and registered in an
identifiable manner, but that confidentiality must be main-
tained. The precise legal framework for cancer registration
will obviously vary between states, but it should provide both
a statement of the principles underlying confidentiality in the
cancer registry, and a practical mechanism for ensuring that
these principles are observed.
A few examples may serve to demonstrate the range of
approaches adopted in relation to confidentiality and the
outcome for cancer registration practice:
Finland
The Finnish Cancer Registry operates under an agreement
between the National Board of Health and the Cancer1140 M.P. COLEMAN et al.
Table II Legal basis of reporting to cancer registries,a by geographic region:
number (per cent)b of registries
Compulsory
Voluntary By law By order Mixed Unknown Total
Africa 4 (100%) - - - 4
S. America 7 (58%) 3 - 2 1 13
N. America 10 (45%) 7 3 2 3 25
Asia 14 (54%) 5 5 2 - 26
Europe 45 (57%) 16 15 3 3 82
Oceania 2 (29%) 4 - 1 4 11
Total 82 (55%) 35 (23%) 23 (15%) 10 (7%) 11 (-) 161
aCancer registries are those invited to contribute to Cancer Incidence in Five
Continents, vol. VI, (in preparation). Data by courtesy ofMs Jean Powell and the
editors ofCancer Incidence in Five Continents. bPercentage ofregistries forwhich
the legal basis of registration is known.
Society of Finland, receiving data from hospitals, physicians
and pathology laboratories. The registry is national, and
began operating in 1953. Cancer notification is required by
law and patients are not asked for consent to register their
cancer. The registry data are used to produce routine statis-
tics on cancer occurrence in the population, for reports to
health authorities, to produce educational material both for
the general public and for the medical profession, and for
scientific research. Scientists needing access to information
including personal identifiers for a given research project
must first obtain permission from the Ministry of Health.
Under the Finnish Law on Person Registers, registered
patients do not have access to their data in the cancer
registry because the files are used, under legal control, only
for statistical and scientific purposes, and are not available
for use by government or other agencies to make decisions
concerning the individual (Hakulinen, 1990). The cancer
registry is widely used for cancer research and its data are
known to be of high quality. The registry has produced
projections of cancer incidence, prevalence and mortality up
to the year 2008 (Hakulinen et al., 1989), and contributed to
an analysis of cancer trends in the Nordic countries
(Hakulinen et al., 1986).
Federal Republic ofGermany
There are several regional registries and a national registry of
childhood tumours. Patients must give consent for their data
to be submitted to some of these registries. In Hamburg,
although 98% of patients who are asked to consent to their
cancer being recorded in the cancer registry do so, a large
and unknown proportion of patients are not asked for their
permission, and are thus not reported to the registry:
15-20% of cancer patients are not fully informed of their
diagnosis, for reasons such as untreated cancer diagnosed in
very old age, death in hospital after admission in extremis,
and confusion (Thiele, 1990). In Saarland, the cancer registry
ceased operating for a year in 1978 while the legal position of
physicians reporting to the registry in relation to
confidentiality was clarified, and an appropriate local law
was passed (Muir & Demaret, 1982). The system under con-
sideration for the cancer registry in Baden-Wurttemberg is
based on reports received from doctors who first encrypt the
patient's name with a computer program. The registry would
use the encrypted code, instead of the name, to identify cases
and to eliminate duplicates. The problems of identification
(same patient coded differently and different patients coded
identically) were examined in a pilot study: incidence was
overestimated by up to 10%. Only 58.8% of 313 doctors
surveyed found it acceptable that the patient's written con-
sent be obtained before registration (Meisner et al., 1990).
In 1983, the German Ministry for Youth, Family Affairs
and Health commissioned a representative survey of 1,500
people to assess the opinions of the general public on cancer
registration - possibly the only such survey ever carried out
(Anon, 1983). Of those interviewed, 88% considered that the
establishment of cancer registries was a valuable measure to
fight cancer, and 78% agreed that their personal data should
be reported and analysed in a cancer registry if they should
develop cancer. Two thirds (66%) considered that the
physician should obtain the patient's consent to report a
cancer to the registry, but that the physician should not have
to insist on this consent before reporting if doing so could
result in additional psychological damage to the patient. It is
of some interest that among the small proportion (12%) of
persons giving an unfavourable opinion on cancer registra-
tion, one-half cited doubts about guarantees of data protec-
tion as their main reason.
The national cancer registry of the ex-German Democratic
Republic, the largest in Europe, has recorded detailed in-
formation on cancers arising in a population of 17 million
since 1953, and has been a particularly rich source of data
for research (see for example Haas et al., 1987). Since the
reunification of Germany in 1990, however, registration has
ceased and the data are not currently available for research
(Sietmann, 1991), while a new legal basis is still being sought
to permit both research with the existing data and continua-
tion of cancer registration (Dickman, 1990).
France
There are a number of regional population-based cancer
registries, the earliest dating from 1975. Many produce
valuable incidence data (Benhamou et al., 1990) and are
actively involved in research. All operate on the basis of
voluntary reporting. Since 1988, seven cancer registers have
been partially funded by the state, and eight more will be so
funded from 1992. The law (article 378 of the Penal Code),
however, does not currently allow a doctor to transmit
identifiable medical data to a doctor not involved in the
patient's treatment, and some doctors refuse to cooperate
with cancer registries for this reason. A 1978 law on privacy
and computerised databases also requires that persons must
be informed of the use to be made of the data. A com-
puterised register of AIDS patients has been created, how-
ever, in which the patient's name and birthdate are irrever-
sibly encrypted at data entry; patients must give written
consent for their data to be entered and can withdraw it at
any time (Dorozyneski, 1988; Thirion et al., 1988). Such a
register can be used to measure incidence and survival, but it
is subject to the same problems of duplicates and selection
bias as in the German cancer registries, and cannot be used
as the starting point for epidemiological studies requiring
access to data on individuals. The paradox has been further
highlighted by an epidemiological study, not ofcancer, but of
the genetics ofmanic depression, in which 30,000 people have
been identified as being at risk of a treatable form of
hereditary chronic glaucoma, genetically linked to manic
depression, and which if untreated can lead to blindness. The
individuals are known by name to the researchers, who are
prevented by law from warning them (Nau, 1991). Legisla-
tion apparently in preparation would resolve this difficulty by
providing adequate controls on individual privacy at the
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Guidelines on confidentiality
Guidelines on confidentiality are required for efficient and
acceptable registration ofcancer. The main objectives of such
guidelines are (Muir, 1991):
(a) to ensure the protection of confidentiality of data
about individuals whose cancer is reported to the registry, so
that information on registered persons cannot reach
unauthorised third parties;
(b) to ensure that cancer registry data are of the best
possible quality;
(c) to ensure that the best possible use is made of cancer
registry data for the benefit of cancer patients, for cancer
control in the population, and for medical research.
The existence of a set of guidelines will not by itself ensure
either high quality or effective use of the data, but such
guidelines define both the conditions under which high
quality data may be collected, linked and stored in an ethical
manner, and a framework to ensure safe and effective use of
the data in a manner consistent with ethical guidelines (Last,
1990). A code of confidentiality will thus help to ensure that
a proper balance can be struck between the individual's right
of privacy and the right of the individual, and that of his or
her fellow citizens, to benefit from the knowledge on cancer
causation, prevention, treatment and survival that can be
derived from cancer registration.
The existence of confidentiality guidelines, and evidence
that they are respected in practice, may be necessary to
reassure members of the public, especially cancer patients,
that data stored in the cancer registry are treated according
to standards of confidentiality that are at least as stringent as
those used in the hospital or the physician's office, and that
the use of these data for research purposes is covered by
adequate safeguards. In some countries, such guidelines may
need to be supported by law or regulation, and to specify
sanctions in the event of breach of confidentiality, as well as
a mechanism for monitoring the adequacy of data security
procedures. Guidelines for confidentiality also provide regis-
try directors with operational guidance, and protect the
reporting physician or institution.
Some cancer registries expressed the need for model
guidelines on confidentiality at the Hamburg meeting of
IACR in 1990, even though most registries already have
formal sets of rules for the maintenance of confidentiality of
their data, often established in cooperation with the compe-
tent local authorities. The guidelines on confidentiality pres-
ented here (annex I) were originally prepared with the help of
several IACR member cancer registries, a national vital
statistics office and the EEC, and revised in the light of
comments received from other IACR member registries. They
have now been further revised and brought up to date, after
circulation for comments to 325 cancer registries and individ-
ual members of IACR.
It should be stressed that these guidelines on confi-
dentiality are not intended en bloc for adoption as a fixed set
of rules by any particular cancer registry. The operating
conditions of cancer registries vary greatly around the world,
and a set of measures considered to be satisfactory in one
cultural context and at a given period of time would prove
inappropriate in another context: there is no simple, global
solution to the problem posed by the maintenance of
confidentiality. Instead, the guidelines are intended to outline
some basic principles, and to provide a set of specific
measures designed to ensure the preservation of confi-
dentiality, from which a registry may select and reformulate,
as necessary, those measures considered to be most useful in
the preparation or revision of a local code of practice on
confidentiality. The guidelines would need to be adapted to
national or local circumstances; they should be used to com-
plement rather than replace existing registry rules, and the
resulting local code of practice on confidentiality would need
to take account of local ethical practice.
An earlier version of the guidelines presented here has
already been translated, adapted and incorporated in this
way by a number ofcancer registries and by a national AIDS
register; it has also been used in the preparation of a training
manual for cancer registry personnel in developing countries
(IARC, in preparation). The earlier version was also adopted
by the EEC Committee of Cancer Experts in May 1989 as
the basis for its recommendation to the EEC Commission on
guidelines for confidentiality in cancer registration.
The chief measures in the code of confidentiality for the
operation of cancer registries are intended:
(a) to define what information is confidential;
(b) to specify measures for the security of data within the
cancer registry;
(c) to require surveillance and periodic review of data
security procedures;
(d) to define the conditions under which confidential data
held by the registry can be released to approved medical
research workers;
(e) to protect the reporting physician and institution.
In their testimony to the US Congress, Gordis and Gold
(1980) laid special emphasis on the point that 'investigations
of the natural history of disease and of the effectiveness of
preventive and therapeutic interventions are of great poten-
tial benefit to society, but the conduct of such studies re-
quires that, with proper safeguards, individually identifiable
data from medical records continue to be made accessible for
medical and epidemiological research'. In a number of coun-
tries, there are now pressing demands both for an absolute
ban on any transfer of personal medical information and for
rapid identification and control of health hazards to the
public. The inherent conflict between these two positions
(sometimes, with scant regard for logic, adopted simultane-
ously) can certainly be resolved, but only if governments can
ensure that regulations designed to safeguard the privacy of
the individual are framed so as to permit - indeed to en-
courage - well-conceived research. With this background, the
guidelines for confidentiality in cancer registration presented
here are intended to be of value for the data subject, the data
supplier and the data user.
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Appendix
Guidelines on confidentiality in the Cancer Registry
International Association of Cancer Registries
1. Purpose of guidelines on confidentiality in the cancer regis-
try
1.1 Aims of document
1.2 Main components
1.3 Background
1.4 Right to privacy
1.5 Use of guidelines
2. Definitions
2.1 Cancer
2.2 Cancer registry
2.3 Cancer registration
2.4 Confidential data
2.5 Treating physician
2.6 Security
3. Role of the cancer registry
3.1 Function of cancer registry
3.2 Legal basis of cancer registration
3.3 Sources of information
3.4 Use of cancer registry data
3.4.1 Clinical use of identifiable data
3.4.2 Transfer of identifiable data for registration
puposes
3.4.3 Use of identifiable data for research
(a) Studies of the causes of cancer
(b) Evaluation of screening
(c) Evaluation of survival from cancer
3.4.4 Use of aggregate data
(a) Research
(b) Health care planning
4. Principles of confidentiality
4.1 Underlying concept of medical confidentiality
4.2 Sharing of confidential clinical information
4.3 Legal protection of data suppliers
4.4 Confidentiality and utility
4.5 Scope of confidentiality measures
4.6 Confidentiality of data on deceased persons
4.7 Indirectly identifiable data
4.8 Methods of data storage and transmission
5. Measures for data security
5.1 Responsibility
5.2 Oath of secrecy
5.3 Physical access to the registry
5.4 Persons with access to registry
5.5 Persons with access to confidential data
5.6 Display of reminders
5.7 Active registration
5.8 Incomplete data
5.8.1 Cases identified from death certificates
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1. Purpose of guidelines on confidentiality in the cancer registry
1.1 Aims of document
The aims of this document, and of the accompanying
article, are:
(a)
(b)
(c)
(d)
(e)
to advance the need for a code of conduct in the
maintenance of confidentiality in cancer registries;
to define the aims of maintaining confidentiality in
cancer registries;
to set out the principles of confidentiality;
to advance guidelines for the preservation of
confidentiality; and
to advance guidelines for the use and release of regis-
try data in accordance with these principles.
1.2 Main components
These guidelines are intended:
(a) to define what information is confidential;
(b) to specify measures for the security ofdata within the
cancer registry;
(c) to propose surveillance and periodic review of data
security procedures;
(d) to define the conditions under which data held by the
registry can be released and the persons to whom it
can be released (data users); and
(e) to protect the reporting physician and institution
(data suppliers).
1.3 Background
The background to these guidelines is presented in the
accompanying article, which should be read in conjunc-
tion with these guidelines.
1.4 Right to privacy
Guidelines for the maintenance of confidentiality are
needed primarily to provide adequate safeguards for the
individual's right to privacy, so that identifiable inform-
ation on persons registered with cancer does not reach
unauthorised third parties, while at the same time preser-
ving the right of the individual, and that of his or her
fellow citizens, to benefit from the knowledge on cancer
causation, prevention, treatment and survival that can be
obtained from cancer registration and research.
1.5 Use of guidelines
Guidelines for the maintenance of confidentiality are also
needed, however, to help ensure that cancer registry data
are of the best possible quality, and that the best possible
use is made of the data, both for the benefit of cancer
patients, for cancer control in the population, and for
medical research. In order for cancer registry data to be
of value for clinical, statistical and research purposes, the
data recorded must be as complete, accurate and reliable
as prevailing circumstances permit. These standards of
quality can only be achieved if both the public and the
physicians and institutions treating cancer patients are
confident that the data required are necessary for the
objectives of cancer registration and medical research,
and that confidential data will be adequately
safeguarded.
These guidelines are not intended to be adopted en bloc
or without modification as a fixed set of procedures for
the maintenance of confidentiality in any particular
cancer registry. Rather they are intended to present the
basic principles of confidentiality, and to provide a set of
measures from which a registry may select and refor-
mulate, as appropriate, those measures considered to be
most useful in the preparation or revision of a local code
of practice on confidentiality.
The applicability of these guidelines will be kept under
review by the IACR, and amendments made as neces-
sary.
2. Definitions
2.1 Cancer
The term 'cancer' is used in this document to imply all
malignant neoplasms, as defined in the International
Classification of Diseases for Oncology, second edition
(Percy et al., 1990).
2.2 Cancer registry
A cancer registry may be defined as an organisation for
the collection, storage, analysis and interpretation of data
on persons with cancer. Cancer registries which limit their
aims to recording particulars of cancer cases seen in a
given hospital or group of hospitals are said to be
hospital-based: such registries are frequently located in
the hospital records department. Cancer registries which
aim to register details of every cancer that occurs in a
defined population, usually those persons habitually resi-
dent within the boundaries of a defined territory or geog-
raphic region, are said to be population-based. Such
registries are often based within a hospital, but may also
be located in a separate building or institution.
Population-based registries may be general (recording all
tumours) or specialised (restricted to a given site-group or
age-group).
2.3 Cancer registration
Cancer registration is the process of continuing,
systematic collection of data on the characteristics of all
cancers and of the persons diagnosed with cancer, and is
the basic activity of a cancer registry.
2.4 Confidential data
For the purposes of this document, any data collected
and stored by a cancer registry which could permit the
identification of an individual patient (data subject) or, in
relation to a particular data subject, of an individual
physician or institution (data supplier) are considered to
be confidential. Data which could permit identification
(identifiable data) include names, address, full date of
birth, date of death, and unique reference numbers (e.g.
national identity numbers).
2.5 Treating physician
For the purposes of this document, the treating physician
may be defined as the doctor primarily responsible for the
patient's cancer treatment; or a doctor to whom the
patients has been referred for additional investigation or
treatment; or the patient's usual physician; the medical
director of the institution where the treating physician is
or was employed when treating the patient in question
may also act on behalf of the physician.
2.6 Security (or data protection) denotes the measures taken
to ensure the maintenance of confidentiality of the regis-
try data, whether stored on paper, microfilm, microfiche
or magnetic media.
3. Role of the cancer registry
3.1 Function of cancer registry
The cancer registry plays a central role in the systematic
collection, recording and analysis of data relating to indi-
viduals with cancer. For each such person 'it is the func-
tion of the registry to record, as fully and as accurately as
may be possible, both a clinical description of the extent
of the disease and also information which will identify the
patient, the tumour, the hospital and the clinicians
involved with the case. When these data are combined
with additional information describing treatment and
subsequent progress (routine follow-up), in which recur-
rences, metastases and further treatment are included,
terminating with the date and cause of death (whether
from cancer or not), a very full and invaluable data bank
can be created' (Waterhouse, 1978).1144 M.P. COLEMAN et al.
3.2 Legal basis of registration
Cancer registration may be based on compulsory or
voluntary notification of cancer patients to the registry.
Compulsory registration may arise from legislation passed
by a parliament or elected legislative body (primary legis-
lation), or from an administrative order issued under the
aegis of a statutory agency such as the Ministry of Health
or a provincial health authority. Some cancer registries
may obtain both voluntary and compulsory notifications,
depending on the source of information: in some areas,
for example, pathologists report voluntarily, while the
Vital Statistics Office is legally required to do so; in
others, pathologists are legally required to report cancers
to the registry, while treating physicians report volun-
tarily.
3.3 Sources of information
Notifications of cancer may be derived from many
sources, such as the treating physician, surgeon,
radiologist or radiotherapist; hospital admissions and
records departments, the hospital discharge report, or
laboratories of pathology, cytology, haematology or
biochemistry; medical records of social security systems;
and coroners and vital statistics offices (death certificates).
Notifications may be submitted on paper records or,
increasingly, on magnetic media. In some areas, registry
employees may visit the source of information to obtain
notifications (active registration), while in others the
sources of information may submit these directly to the
registry (passive registration). Many registries use both
active and passive methods of registration.
3.4 Use of cancer registry data
The purposes for which data collected by the cancer
registry are used should be clearly defined. Cancer regist-
ries are important sources of data, both for clinical pur-
poses and for research intended to advance understanding
of the causes, occurrence and outcome of cancer. Such
data may be either identifiable or aggregate (anonymous),
depending on the nature of the research. Some examples
of the use of cancer registry data in relation to
confidentiality are outlined here: the list is not intended to
be exhaustive, but to identify major categories of use.
3.4.1 Clinical use of identifiable data
Clinical use of identifiable data relating to patients
registered with cancer arises in the context of their diag-
nosis, treatment and follow-up by the treating
physician(s). Availability to the treating physician of
identifiable data may enable duplication of diagnostic
procedures to be avoided, may facilitate exchange of
information between treating physicians, and may assist
the physician to evaluate the outcome of treatment in
individual patients or in groups of patients. Identifiable
data required for such clinical purposes may therefore be
provided to the treating physician on request, and in
accordance with the procedures outlined in section 6, in
order to assist the physician in the management of his or
her patients with cancer.
3.4.2 Transfer ofidentifiable datafor registration purposes
In two circumstances, registries may need to transfer
identifiable data to other cancer registries for the pur-
poses of complete registration. The first case involves a
tumour diagnosed in a person who proves to be resident
in the territory of another, usually adjacent, registry. The
second case involves regional registries which contribute
data to a larger or national registry, or specialised regist-
ries which also contribute data to a general population-
based registry. In each case, data may be transferred for
the purposes of complete and accurate registration, pro-
vided that the recipient registry adheres to comparable
standards of confidentiality.
3.4.3 Use of identifiable data for research
(a) Studies of the causes of cancer
Case-control and cohort studies help in identifying the
causes of cancer. Both types of study require information
about individuals with cancer. In a cohort study, for
example, linking the cohort members against the cancer
registry files (or against a file of death certificates) enables
cancers arising in the cohort to be detected. This has
proved a highly efficient, economical and confidential
method of detecting risk. Such linkages may be manual,
computerised or both, and while linkage always requires
knowledge of the identity of individuals with cancer, the
resulting publications always present anonymous or agg-
regated data. Registries are frequently used as a source of
cases (and sometimes also of controls) for case-control
studies: the value of these studies for identifying risk
factors is enhanced by the availability of a representative
sample of tumours diagnosed in the population.
(b) Evaluation of screening
Cancer registries play a major role in the evaluation of
screening programmes, by providing information to
enable the assessment of whether, in comparison to an
unscreened population, invasive cancer, e.g. of uterine
cervix or breast, develops less frequently and mortality
decreases in a screened population or subgroup. This
requires comparison of lists of individuals with cancer
detected by the screening programme with cancer registry
files. The cancer registry may thus be essential for ade-
quate evaluation of a population-based cancer screening
programme, providing information not available in any
other way.
(c) Evaluation of survival from cancer
By matching death certificates to cancer notfications
received by the registry, it is possible to assess the sur-
vival of all persons with cancer in a defined population.
Survival from cancer in the population as a whole is
frequently quite different from that reported for selected
series ofpatients (e.g. in clinical trials). Such data may be
used to evaluate the extent and speed with which new or
improved cancer treatments are incorporated into routine
clinical practice. It is also possible to assess population
survival for a given cancer by the extent of spread at
diagnosis, or by type of treatment. This type of research
is only possible if the registry can link identifiable cancer
registrations with death certificates; such evaluation of
cancer survival is now routine practice in many regist-
ries.
3.4.4 Use of aggregate data
(a) Research
One of the most important contributions of the cancer
registry is to provide current data on the incidence of
various types of cancer, and on variations in incidence by
age, sex, place of birth, occupation, ethnic group, etc.
These data can also be used to study differences in his-
tological types and between urban and rural areas, and to
examine trends in incidence over time. Only aggregate,
anonymous data are used in such studies.
(b) Health care planning
Information provided by the cancer registry on the
numbers of cancer patients can help health authorities in
various ways, including long-term planning for the pro-
vision of medical facilities and the training of health care
professionals; establishment of priorities and programmes
for cancer control; evaluation of the effects of interven-
tion; and estimation of the numbers of cancer patients in
the future (projections). For all these purposes the iden-
tity of individual cancer patients is neither needed nor
provided: only aggregate data are used.
4. Principles of confidentiality
4.1 Underlying concept of medical confidentiality
The set of principles outlined below relates to the preser-
vation of confidentiality in connection with or during the
process of collection, storage, use, and transmission of
identifiable data by the cancer registry. A cancer registry
must maintain the same standards of confidentiality in
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doctor-patient relationship; this obligation extends
indefinitely, even after the death of the patient.
These guidelines are intended to help ensure the
confidentiality of data about individuals whose cancer is
reported to the registry, so that information on registered
persons cannot reach unauthorised third parties.
4.2 Sharing of confidential clinical information
For serious diseases such as cancer, 'in modern medical
practice, the doctor can seldom be the sole confidant,
since effective care involves others, both medical and
non-medical, technical and clerical, who provide services
and manage the health care institutions' (Medical
Research Council, 1985). Despite this essential dispersion
of confidential information within the clinical team,
ultimate responsibility for the maintenance of
confidentiality remains with the treating physician. The
treating physician who provides information to a cancer
registry about a patient with cancer therefore has the
right to expect that the registry observes strict rules of
confidentiality (see section 5.1).
4.3 Legal protection of data suppliers
Unless cancer is a disease which must be notified to a
cancer registry by virtue of a law or administrative order,
the data recorded by the cancer registry are supplied on a
voluntary basis by the physician or institution. In some
countries, therefore, it may be necessary for the registry
to ensure that there is at least legal authority for
physicians to report cancer, in order to protect data
suppliers from legal action for breach ofconfidentiality in
submitting identifiable data to the cancer registry.
4.4 Confidentiality and utility
Effective operation of the cancer registry depends on the
continuous supply of confidential information from
several sources, notably clinicians, pathologists and vital
statistics offices. These data suppliers can only be
expected to continue to provide such information if the
cancer registry can be trusted to maintain confidentiality
and to make good use of the data. Data suppliers will
therefore need to be satisfied that the registry adheres to
an adequate set of guidelines on confidentiality, and that
data of high quality are being collected and used for the
benefit of cancer patients and cancer research.
4.5 Scope of confidentiality measures
Maintenance of the confidentiality of identifiable data
held by the cancer registry should extend beyond inform-
ation on cancer patients and those notifying them (data
subjects and data suppliers), to include identifiable data
from medical records, census data, interview records,
death certificates and lists of members of industrial
cohorts or other study populations which may be stored
in or provided to the cancer registry as part of its routine
operations or for research projects.
4.6 Confidentiality of data on deceased persons
Data on deceased persons held in the cancer registry
should be subject to the same procedures for
confidentiality as data on living persons, even though
death certificates or related information may be available
from other sources, or in the public domain.
4.7 Indirectly identifiable data
Individual records from which names and address have
been removed, but from which it might still be possible to
identify an individual indirectly by use of the remaining
data, e.g. an identity number, should also be subject to
the measures for preservation of confidentiality in the
cancer registry.
4.8 Methods of data storage and transmission
Guidelines for the maintenance ofconfidentiality are app-
licable not only to the storage of identifiable data on
computers, but also to the storage of such data in the
form of paper records, microfilm, microfiche and
magnetic media, and their transport or transmission by
registry personnel in any of these formats. The proce-
dures involved may differ, but the underlying principle is
the same.
5. Measures for data security
5.1 Responsibility
The Director of the cancer registry is responsible for
maintaining the confidentiality of identifiable data. The
Director must ensure that all the registry staff are aware
of their individual responsibilities with respect to
confidentiality, and that the security measures adopted by
the registry are known and adhered to by all staff. Depend-
ing on the country, the Director's responsibility for data
security may need to be defined in appropriate legislation,
or by administrative order, or in other documents estab-
lishing the status and function of the registry.
5.2 Oath of secrecy
Duly trained and specialised staff should be appointed to
run the cancer registry in accordance with its aims and
rules of operation. It is recommended that, as part of
their contract of employment or conditions of service,
each member of the registry staff be required to sign a
special declaration to the effect that they will not disclose
confidential information held by the cancer registry to an
unauthorised person at any time, or to any other person
except as permitted within the context of the registry's
guidelines on confidentiality. The terms of the contract of
employment should make it clear that breach of this
undertaking will result in disciplinary action which may
involve a fine or dismissal. This declaration of secrecy
shall remain in effect even after the staff member ceases
to be employed in the cancer registry.
5.3 Physical access to the registry
Suitable locks and alarm systems should be installed to
control physical access to the registry. Consideration
should be given to the use of special locks with entry
codes, or electronic methods of controlling access, and to
the maintenance of a record of persons other than staff
members who enter the registry.
5.4 Persons with access to registry
Unauthorised access to the cancer registry should be
prevented. The Director of the registry should maintain
an up-to-date list of all persons authorised to enter the
registry.
5.5 Persons with access to confidential data
The Director of the registry should maintain an up-to-
date list of registry staff members indicating the type of
data to which each of them has access (with the corres-
ponding level of computer security, if relevant).
5.6 Display of reminders
It is recommended that notices reminding staff of the
need to maintain confidentiality be prominently displayed
within the registry.
5.7 Active registration
Registry staff assigned to collect information at source
(active registration) are responsible for maintaining the
confidentiality not only of identifiable data they may
collect on persons with cancer for the registry, but also of
other information of a confidential nature which they
may read or hear at the source.
Cancer registries using active methods of registration
should give consideration (a) to providing staff with a
lockable attache-case for the transport of confidential
information; (b) to advising staff on other measures to
avoid accidental loss of such material; and (c) to pro-1146 M.P. COLEMAN et al.
viding staff with suitable means of identification as an
employee of the cancer registry. The identity of such staff
should be made known to the relevant person(s) at each
of the sources which they visit to collect information for
the registry, and where possible, changes in personnel
should be notified to these sources in advance.
5.8 Incomplete data
If it is necessary for the registry to request additional
information from a source concerning a particular regist-
ration, for example to check an address or date of diag-
nosis, this should be done by sending a confidential
enquiry to a named individual at the source concerned.
One technique used by certain registries is to arrange for
the computer to generate standardised requests for miss-
ing data items which are then mailed under confidential
cover, or electronically.
5.8.1 Cases identified from death certificates
Comparison of registry files with death certificates may
reveal a death certified as due to a cancer not apparently
registered in life. Registries which seek further inform-
ation about cases first identified from a death certificate
should request information from the certifying physician
or the vital statistics office, according to local circums-
tances; if no further information can be obtained, the
registry must decide whether to register such cases solely
on the basis of the death certificate ('death certificate
only', or DCO).
5.8.2 Matching of data files
The registry files may need to be matched against other
computer files, either to provide missing data items or for
the purposes of research. If it is necessary for such mat-
ching to be undertaken outside the registry, e.g. in a vital
statistics office or on an external computer, the registry
should first ensure that the confidentiality of its records
will be preserved by the agency receiving the registry
data.
5.9 Transmission of information
Authority to transmit identifiable data from the registry,
whether by mail (in paper or machine-readable form), by
telephone or by electronic means, should be obtained
before transmission from the Director or other nominated
staff member to whom specific responsibility for such
transmission has been delegated.
5.9.1 Postal services
Cancer registries may need to receive and send cancer
notifications and other confidential data by post in writ-
ten or printed form. Consideration should be given (a) to
the use of registered post or other forms of recorded
acceptance and delivery by the postal service; (b) to the
possibility of sending lists of names and other identifiable
data separately from any other information being trans-
mitted; (c) to the use of double envelopes, the external
envelope giving a general address, and the internal
envelope being marked for opening only by a named
individual. If regular postal services are considered
unreliable, use ofa courier service may be envisaged: such
a courier service should provide a written undertaking to
maintain the security of cancer registry material.
5.9.2 Magnetic or electronic media
When identifiable data are sent by post on magnetic
tapes, diskettes or in other machine-readable form,
suitable precautions should be taken to ensure the
physical security of the material in transit (as in the
preceding paragraph). In addition, steps should be taken
to ensure that the data cannot easily be read by an
unauthorised person. Among the precautions which might
be taken are:
(a) encrypting of names at various levels of complex-
ity;
(b) sending the tape, diskette (etc) containing names,
address and other identifiable data separately from the
media containing tumour-related or other data, using a
link number to enable reconstitution of the record by the
intended recipient, and giving maximum security to the
media containing identifiable data.
5.9.3 Electronic transmission
Many cancer registries use computers which are 'stand-
alone', i.e. are not electronically linked to any other
computer; these are usually owned by or dedicated solely
to the cancer registry, and sited on its premises. Such
computers cannot be used to transmit data electronically.
Computer systems capable of electronic transmission may
be classified into three groups:
(a) microcomputers with a 'modem', capable of transmit-
ting and receiving via a standard telephone line;
(b) larger installations, still dedicated to the registry but
with a fixed connection to an electronic communication
network; and
(c) installations which the cancer registry shares with
other users, such as a health ministry or university
department computer.
As information systems evolve, an increasing amount of
data is being sent to cancer registries by electronic means,
usually via telephone lines dedicated to such purposes (i.e.
not used for speech). A registry may also send its data for
storage on a computer shared with another agency by this
means (class (c) above).
Consideration should be given to measures such as en-
crypting names, and sending identifiable data separately
from tumour and other data, with link numbers or codes,
as outlined in the preceding section. Such measures would
be applicable to data sent electronically either to a com-
puter or to a telefax.
5.10 Use of telephone
It must be clearly recognised that use of the telephone,
although convenient, may give rise to a breach of
confidentiality.
No identifiable data or confidential information of any
kind should be given to telephone callers by registry staff
unless the caller is already an authorised recipient of such
information, can give proof ofidentity and can justify the
need to have the information by telephone rather than in
writing. Identity should be requested by asking the caller
to give his or her name, telephone number, address and
position or title. After verification, a member of registry
staff authorised to divulge such information should do so
by calling back the person requesting it.
The need for the registry to pass identifiable information
to external callers by telephone should be infrequent. One
example might be where a clinician requests specific in-
formation concerning a patient in the context of manag-
ing that patient's disease.
5.11 Use of computer
Various physical and electronic measures are available to
prevent unauthorised access to information held on the
computer. The electronic measures are subject to rapid
evolution, and will only be discussed in general terms
here.
5.11.1 Data entry
Where feasible, the computer terminal(s) used for data
entry may be placed in a separate room, access to which
is restricted.
Other precautions may include:
(a) use of user names and passwords which do not
appear on the screen when typed;
(b) change of passwords at intervals;
(c) automatic logging by the computer of all successful
and unsuccessful attempts to enter the system, with
regular checks of this log against written records of ses-
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5.11.2 Use of database
Registry staff and other authorised users of its computer
database should also be subject to the relevant precau-
tions outlined in the preceding paragraph. Where possi-
ble, consideration should also be given to providing
different levels of access to the database, such that only
users authorised to gain access to identifiable data can do
so.
5.11.3 Demonstrations
Cancer registries are frequently asked to demonstrate
their computer system. When such demonstrations are
given, it is recommended that the data used be fictitious
or anonymised, and that the screen displays be labelled
'Demonstration', so that visitors are aware of this. For
such purposes, it may also be possible to have a separate
'dummy' dataset, accessed by a special password and
used only for demonstrations. The data used might be
real, but with the names and addresses removed, scramb-
led or substituted with fictitious ones.
5.11.4 Backup
The computer database will usually be backed up to tapes
or diskettes on a regular basis (daily, weekly, etc), for
physical storage outside the registry as a precaution to
avoid loss of the entire database in the event of extensive
damage to the registry by fire or other hazards. It is
advisable that such copies of the electronic database be
stored in a locked fire-proof safe or an equivalent secure
location, if possible on the premises of an agency such as
a professional medical society, health ministry, medical
ethical committee or legal authority.
5.12 Unauthorised access to computer system
It must be recognised that some persons may attempt to
gain remote electronic access to computer systems, often
to show that this is possible rather than to examine the
data. It is unlikely that registries using computer systems
to which remote electronic access is possible can provide
absolute protection against any such attempt at
reasonable cost. The level of security built in to such
systems should at least be capable of foiling casual
attempts to gain unauthorised access. Consideration
should also be given to obtaining expert advice on enhan-
cing the electronic security of such computer systems; this
aspect of security should be regularly reviewed. Although
it may not always be possible, in this context it is
preferable that the cancer registry have an isolated data
processing system.
5.13 Paper storage
Electronic methods of storage of identifiable data in
cancer registries are now almost universal, but most regis-
tries also store a considerable amount of data on paper.
Such material may include cancer registry notification
forms, medical records, copies of pathology reports,
copies of death certificates, etc. It is usually not prac-
ticable to keep names and other identifiable data
separately from such material. Unlike data in computers,
which can be readily protected against all but the most
determined intruder, paper records are accessible to
casual inspection, and require no special expertise to gain
access. Consideration must therefore be given to keeping
this material as secure as possible. Specific measures that
may be considered include:
(a) defining who has access to the registry premises;
(b) defining which members of staff have access to the
room where these materials are kept;
(c) providing lockable storage cabinets in which all
confidential materials should be stored at the end of a
working session; and
(d) ensuring that persons not authorised to do so (e.g.
cleaning personnel) are not able to scrutinise paper or
other physical records containing confidential data.
5.14 Disposal ofpaper records
A suitable policy should be developed for the safe dis-
posal of waste paper and other physical records contain-
ing identifiable data. As in certain hospital records
departments, many registries microfilm the paper records
of registered persons at a certain interval after death, and
destroy the paper record. Such destruction would nor-
mally involve shredding. Where the volume of
confidential records to be destroyed is large, it may be
necessary to employ specialised services for the safe dis-
posal of confidential waste.
5.15 Review of security procedures
It is recommended that cancer registries undertake formal
review of their security procedures at appropriate inter-
vals. It may be helpful to recruit the services of specialist
advisers to ensure that the registry's procedures for the
maintenance of confidentiality are up-to-date, and cover
all aspects of the registry's operations.
6. Release of data
One aim of all cancer registries is to make data usefully
accessible for clinical purposes, for research and for use
in health care planning (section 3.4). Some of these uses
involve the release of identifiable data on individuals
registered with cancer. Whilst adhering to its guidelines
on the maintenance ofconfidentiality, therefore, the regis-
try must also develop procedures to deal with requests for
the release of confidential data.
6.1 Responsibility for data release
The Director of the registry would normally decide
whether a request for information including confidential
data on individuals can be met within the registry's
guidelines, or whether wider consultation is required, for
example through a scientific committee, internal review
board or ethics committee competent to deal with such
requests.
6.2 Limitations on data release
In the absence of written consent from all the parties
concerned, a cancer registry should not release
identifiable data either about a registered person (data
subject) or, in relation to such a person, about a treating
physician or institution (data supplier), for any purpose
other than those outlined for clinical and research pur-
poses (section 3.4). Enquiries may be received for
identifiable data concerning individuals (who may or may
not have a cancer recorded at the registry) from agencies
such as pension schemes, health care cost reimbursement
schemes or industrial disease compensation panels, or in
the context of medical examination for life assurance or
employment. Such requests for information, even from
physicians, should be refused in terms which do not
indicate whether the individual is or is not registered, and
the enquirer should be asked to obtain information
directly from the subject or the subject's treating
physician.
6.3 Release of identifiable data for clinical purposes
Physicians who request data in the context of treating a
patient registered with cancer should be given unrestricted
access to the registry's data for that patient.
6.4 Release of identifiable data for research
The cancer registry should consider the release of
confidential data only if the request is received in writing,
if the nature of the request falls within the accepted range
of uses of registry data, and if the request meets the
registry's requirements for safeguarding the confidentiality
of its data. The request should therefore be expected to
include:
(a) the exact purpose for which the data are needed;
(b) the nature of the information required, and a
justification of the need for confidential data; and
(c) the name and position of the person(s) who would
have access to the confidential data; and
(d) the period of time for which the data would be used,
and the way in which the data would be disposed of after
the elapse of this period.1148 M.P. COLEMAN et al.
6.5 Release of aggregate data
Aggregate data in tabular or comparable formats (e.g. the
numbers of persons registered with a given cancer by age,
sex, year, etc) would not normally be subject to con-
straints on release in relation to confidentiality. For small
geographic areas, however, tables containing cells with
very few entries could in theory make it possible for
individuals to be identified, and the registry should con-
sider suitable measures to avoid this.
6.6 Provision of data to individuals
The cancer registry should not in general inform individ-
uals whether or not there are data about them in the
registry, unless required to do so by law: such requests
should be referred to the treating physician or to the
person responsible for data protection in the treating
institution. It is preferable that any information about
individuals be divulged through the treating physician,
rather than directly to the person concerned.
6.7 Studies involving several registries
Research projects involving the provision of data about
individuals from many cancer registries, sometimes in
different countries, have provided valuable information
about cancer risk. Whilst it may be necessary for individ-
uals to be identifiable within the context of such studies,
identifiable data should not normally be transmitted to
other registries or countries. Each subject may be
allocated a suitable number by which his or her record
can be traced in the cancer registry of origin by registry
staff, for data verification within the study. This number
can then be used instead of the subject's identity in data
files contributed to the study coordinating centre.
When the study design requires that identifiable data can
be transmitted across registry or national borders, and if
legislation permits, then such transferred data should
remain subject to the same rules of confidentiality as in
the registry of origin. Cancer registries participating in
such studies should satisfy themselves that their data will
be treated accordingly. It may be advisable that data for
such studies be transferred to a suitable independent
research agency or a reserach centre recognised by the
World Health Organization.
6.8 News media
Cancer registries are frequently approached by the press
for information on cancer. It is recommended that all
such enquiries be referred to the Director or other
nominated staff member to whom specific responsibility
for dealing with the press has been delegated.
6.9 Conditions for release of data
The Director of the registry should obtain satisfactory
evidence that the intended recipient of data requested for
research purposes will:
(a) observe the same principles of confidentiality as are
observed by the staff of the cancer registry;
(b) comply with all restrictions imposed by the registry
on the use of the data, in particular that they will not be
used for purposes other than those agreed at the time of
provision of the data, and that they will not be com-
municated to other parties;
(c) not contact registered persons (or relatives of persons)
whose identities have been provided in confidence by the
cancer registry (e.g. for research based on interview)
except if written authorisation to do this has first been
obtained from the treating physician in each case: in some
countries the project may also need to be approved by an
ethical committee;
(d) ensure that any publication of the results of research
will not enable any individual to be identified; and
(e) return or destroy in an approved manner all data
which are no longer required for the purpose specified in
the request.
6.10 Guidelines for release of data
It is recommended that registries consider preparing a
document which sets out the procedures and criteria app-
licable to the release of their data, especially the release of
identifiable data for research. Such a document could be
provided to researchers requesting identifiable data.
Recipients of identifiable data approved under these pro-
cedures should also be asked to provide signed com-
mitments to respect the confidentiality of such data and
to adhere to the registry's guidelines for the use of the
data, including destruction or return of the data on com-
pletion of the research.
6.11 Cessation of cancer registration
Each cancer registry should develop a policy for the
actions to be taken in the event that the registry ceases
operation. Consideration should be given to methods of
storage of the registry database in an archive, so as to
preserve its utility for the purposes outlined above (sec-
tion 3.4) whilst ensuring the maintenance of
confidentiality. It is recommended that, where possible, a
suitable agency be identified, in advance, to store the
registry archive for a minimum of 35 years. The agency
should undertake to make the database available for the
purposes defined by the registry and under the same rules
ofconfidentiality as applied by the registry. Consideration
should also be given to the data selected for storage and
the method of archiving. Selected paper records might be
microfilmed, and selected computer files archived on elec-
tronic media. Safe disposal of confidential records not
included in an archive deposit should also be planned in
advance.
7. Summary of conclusions and recommendations
7.1 Principles of confidentiality and the role of the cancer
registry
7.1.1 The purposes for which data collected by the cancer
registry are to be used should be clearly defined
(section 3.4).
7.1.2 Identifiable data may be provided to a clinician for
use in the treatment of cancer patients (section
3.4.1).
7.1.3 Identifiable data may be transferred to a col-
laborating registry for the purposes of complete
and accurate cancer registration (section 3.4.2).
7.1.4 The cancer registry must maintain the same stan-
dards of confidentiality as customarily apply to the
doctor-patient relationship; this obligation extends
indefinitely, even after the death of the patient (sec-
tion 4.1).
7.1.5 It may be necessary to ensure that physicians have
legal authority to report cancer, where registration
is not compulsory (section 4.3).
7.1.6 The scope of confidentiality extends not only to
identifiable data about data subjects and data supp-
liers, but also to other directly or indirectly
identifiable data stored in or provided to the regis-
try (sections 4.5 and 4.7).
7.1.7 Data on deceased persons should be subject to the
same procedures for confidentiality as data on liv-
ing persons (section 4.6).
7.1.8 Guidelines for confidentiality apply not only to
data stored on computer, but also to data stored in
other forms, such as paper, microfilm, microfiche,
etc (section 4.8).
7.2 Measures for data security
7.2.1 The Director of the registry is responsible for
data security (section 5.1).
7.2.2 The staff of the registry should sign, as part of
their contract of employment, a declaration that
they will not release confidential information to
unauthorised persons. This declaration should
remain in force after cessation of employment
(section 5.2).
7.2.3 Suitable locks and alarm systems should be in-
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of persons authorised to enter the registry should
be maintained by the Director (sections 5.3 and
5.4).
7.2.4 The Director should maintain a list of staff
members indicating the nature and extent of their
access to registry data (section 5.5).
7.2.5 Notices reminding staff of the need to maintain
confidentiality should be prominently displayed
(section 5.6).
7.2.6 Registry staff are responsible for the confidenti-
ality of all data encountered during active regis-
tration (section 5.7).
7.2.7 Cancer registries should consider provision of
proof of identity to staff engaged in active regis-
tration (section 5.7).
7.2.8 Requests to complement incomplete data should
be addressed to a named individual at the source
by confidential enquiry (section 5.8).
7.2.9 Identifiable data should not be transmitted by any
means (post, telephone, electronic) without ex-
plicit authority from the Director or a staff
member to whom such authority has been dele-
gated (section 5.9).
7.2.10 Cancer registries should consider use of registered
post or courier services for confidential data, as
well as separating names from other data for
transmission (section 5.9.1).
7.2.11 Precautions should be taken for both physical
and electronic security of confidential data sent
on magnetic or electronic media (section 5.9.2).
7.2.12 The telephone should be used rarely, if at all, for
confidential information, and only under specific
constraints, by a staff member specifically
authorised to do so (section 5.10).
7.2.13 Use of the computer for confidential data should
be controlled by electronic and, if possible,
physical measures to enhance the security of the
data, including use of a separate room, use of
passwords, automatic logging of all attempts to
enter the system, and different levels of access to
data (section 5.11).
7.2.14 Demonstrations of the computer system should
be done with separate and fictitious or anony-
mised data sets (section 5.11.3).
7.2.15 Special precautions should be taken for the
physical security of electronic backup media (sec-
tion 5.11.4).
7.2.16 Consideration should be given to obtaining expert
advice on security against unauthorised remote
electronic access, if it is not possible to use
isolated data processing systems (section 5.12).
7.2.17 Measures should be taken to ensure the physical
security of confidential records held on paper,
microfilm, microfiche, etc (section 5.13).
7.2.18 A policy should be developed for safe disposal of
confidential waste (section 5.14).
7.2.19 Security procedures should be reviewed at suitable
intervals, and consideration should be given to
obtaining specialist advice (section 5.5).
7.3 Release of registry data
7.3.1 Release of cancer registry data for clinical pur-
poses, for research and for health care planning is
central to the utility of the registry, and the regi-
stry should develop procedures for data release
which ensure maintenance of confidentiality (sec-
tions 3.4 and 6).
7.3.2 The Director of the registry is responsible for
deciding if requests for data meets the registry's
guidelines on confidentiality (section 6.1).
7.3.3 Identifiable information about data subjects or
data suppliers should not be released for purposes
other than those previously specified by the regi-
stry, unless all parties concerned provide written
consent for such release (section 6.2).
7.3.4 Physicians should be given access to data needed
for management of their patients (section 6.3).
7.3.5 Requests for data to be used for research should
include a suitably detailed justification of any
need for identifiable data (section 6.4).
7.3.6 Measures should be taken to avoid the possibility
that individuals might be identifiable from tables
containing cells with very few entries (section
6.5).
7.3.7 Data should not normally be provided to indivi-
duals about themselves, unless required by law
(section 6.6).
7.3.8 For multi-registry or international studies, identi-
fiable data should not normally be transmitted to
other registries or countries (section 6.7).
7.3.9 Enquiries from the press should be referred to the
Director of the registry or to a staff member
nominated for this purpose (section 6.8).
7.3.10 The Director of the registry should obtain evi-
dence that researchers using registry data will
adhere to the registry's guidelines on confidenti-
ality of the data (section 6.9).
7.3.11 It is recommended that registries provide a docu-
ment describing their procedures and criteria for
release of data (especially identifiable data) to
researchers who request access to the data (sec-
tion 6.10).
7.3.12 It is recommended that advance plans should be
made for the possible cessation of registry
activity, in order to maintain the subsequent
utility of the database whilst safeguarding the
confidentiality of its data (section 6.11).
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